bYoRNA: Funding, Investors & Team (Sep 2026)
bYoRNA is a French biotechnology company specializing in the cost-efficient, scalable bioproduction of high-quality therapeutic messenger RNA (mRNA) using engineered eukaryotic cells, particularly recombinant yeast. Their disruptive platform enables the production of long, humanized mRNA with lower immunogenicity and higher integrity compared to traditional in vitro enzymatic synthesis. This technology aims to mass produce mRNA for gene therapies, cancer vaccines, and infectious disease vaccines at a fraction of current costs, making mRNA therapeutics more accessible globally.
bYoRNA has raised $1.8M across 1 funding round on record, the most recent a Pre-Seed of $1.8M announced in Jul 2025.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
bYoRNA Company Profile and Key Stats
Latest funding round on record: Jul 2025.
bYoRNA Funding Rounds
bYoRNA Founders and Leadership Team
No contact details are on record for this team yet.
bYoRNA Funding Compared to Other Biotechnology Startups
bYoRNA's latest round of $1.8M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like bYoRNA in Biotechnology and Bordeaux
Companies Similar to bYoRNA
Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of…
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid…
NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for…
Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…
One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…
Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…
NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the…
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…
Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient…
Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…
AB Science was established in 2001 by a group of individuals in the medical and business fields who are…
bYoRNA Funding FAQs
What does bYoRNA do?
bYoRNA is a French biotechnology company specializing in the cost-efficient, scalable bioproduction of high-quality therapeutic messenger RNA (mRNA) using engineered eukaryotic cells, particularly recombinant yeast. Their disruptive platform enables the production of long, humanized mRNA with lower immunogenicity and higher integrity compared to traditional in vitro enzymatic synthesis. This technology aims to mass produce mRNA for gene therapies, cancer vaccines, and infectious disease vaccines at a fraction of current costs, making mRNA therapeutics more accessible globally.
How much funding has bYoRNA raised?
bYoRNA has raised $1.8M across 1 round on record. The most recent is a Pre-Seed of $1.8M announced in Jul 2025.
When did bYoRNA last raise funding?
bYoRNA's most recent funding round on record is a Pre-Seed of $1.8M, announced in Jul 2025.
Who founded bYoRNA?
FundedIQ lists Thierry Ziegler (Founder) at bYoRNA.
Where is bYoRNA headquartered?
bYoRNA is based in Bordeaux, Aquitaine, France.
How many employees does bYoRNA have?
bYoRNA is in the 11-50 employee band.
How does bYoRNA's funding compare to other Biotechnology startups?
bYoRNA's latest round of $1.8M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's bYoRNA Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for bYoRNA is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.